The number of long-term survivors of patients with acute myeloblastic leukemia (AML) has increased as a result of the progress of chemotherapy. We examined the recovery of peripheral blood lymphocytes (PBL) subset after chemotherapy to clarify the reconstitution of the immune system in AML. Thirty patients with AML in complete remission (CR) were entered into the study. 
Introduction
Recent advancements in chemotherapy have greatly benefited the longevity of many patients with acute myelogenous leukemia (AML) and many of these patients survive without disease for years. 1, 2 With the use of techniques such as polymerase chain reaction (PCR), minimal residual disease (MRD) can be detected at an early stage after chemotherapy in the patients who are in complete remission (CR). Some investigators show that the elimination of MRD detected by PCR is not always necessary for long-term survival, 3 however, it has been also shown that patients with a higher level of MRD appeared to have an increased chance of relapse and that MRD disappears in conjunction with the duration of CR in some patients with acute leukemia. 4, 5 It is conjectured that the immune surveillance system must play an important role in this process. The reconstitution of the hematopoietic and immune systems after bone marrow transplantation (BMT) have been studied exten-sively, 6 but there are only a few reports about the reconstitution of the immune system long after chemotherapy for AML. [7] [8] [9] In order to clarify the process of the recovery of the immune system after chemotherapy, we examined, by twocolor flow cytometry, the subpopulations of peripheral blood lymphocytes (PBL) in patients with AML who were in CR.
Materials and methods

Patients
Thirty patients with AML in CR were entered into this study. There were 12 males and 18 females; one M0, six M1, 14 M2, three M3, two M4 and four M5 according to the FrenchAmerican-British (FAB) classification. The age ranged from 21 to 78 years (median age, 46 years). The duration of diseasefree survival after the completion of chemotherapy ranged from 5 to 144 months (median, 35 months). In the Japan Adult Leukemia Study Group (JALSG) protocols (AML 85, 87, and 89), 1,2 the remission induction therapy (BHAC-DMP) consisted of a 10-14-day daily treatment of 6-mercaptopurine /day) was administered on days 1 and 4. After having achieved CR, patients received three additional 6-day courses of consolidation therapy with the same initial drug combination, except that DNR (25-40 mg/m 2 /day) was administered on days 1 and 3. After completing consolidation chemotherapy, patients began a maintenance chemotherapy which consisted of two regimens administered alternately every 5 weeks for a period lasting 1. years. One regimen was a 5-day course of the same BHAC-DMP therapy as the patient's initial consolidation therapy, except that DNR was administered on days 1 and 2. The other consisted of a combination of vincristine (VCR) (1.5 mg/m 2 /week for 2 weeks), cyclophosphamide (CPM) (550 mg/week for 2 weeks), 6MP (70 mg/m 2 /day for 2 weeks), and PSL (20 mg/m 2 /day for 2 weeks).
Cell preparation
Heparinized blood samples were obtained from the patients and 20 normal adult volunteers (the age range, 21 to 65 years), and all patients and volunteers were healthy and did not have any signs and symptoms of infection at phlebotomy. The blood was diluted with phosphate-buffered saline (PBS) and peripheral blood mononuclear cells were separated by centrifugation over a Ficoll-Hypaque gradient. Cells were washed twice in PBS and resuspended at 5 × 10 6 /ml in PBS with 0.001% NaN 3 , and then immediately stained with monoclonal antibodies.
Monoclonal antibodies
The monoclonal antibodies (mAb) used are antibodies which have been extensively characterized. CD2 (OKT11-FITC), CD3 (OKT3-FITC), CD4 (OKT4-FITC), CD5 (T1-PE), CD8 (OKT8-FITC), and HLA-DR (OKDR-PE) were purchased from Ortho Diagnostic Systems (Raritan, NJ, USA), and CD16 (Leu11-PE, Leu11c-PE), CD20 (Leu16-FITC), and CD57 (Leu7-FITC) were purchased from Becton Dickinson (San Jose, CA, USA), and CD45RA (2H4) and CD56 (NKH1) were purchased from Coulter Immunology (Hialeah, FL, USA).
Cell labeling
Phenotypic analysis was performed either by indirect immuno fluorescence with FITC-conjugated goat anti mouse IgG (Ortho Diagnostic Systems) or by two-color analysis using directly labeled antibodies. Commercial mAbs were used according to the manufacturer's directions. Double labeling was accomplished in two steps: 10 6 cells were incubated with FITC-labeled mAb at 4°C for 30 min, washed twice, then incubated at 4°C for 30 min with the PE-labeled mAb, washed twice and resuspended in 2 ml PBS with 0.001% NaN 3 . Labeling steps were reversed when PE labeled Leu11, Leu11c, and NKH-1 were used.
Flow cytometric analysis
Ortho Cytron (Ortho Diagnostic Systems, Tokyo, Japan) was used for analysis. The fluorescence intensity of cells was determined and displayed as a histogram plotting fluorescence vs cell number. Cell populations were selected from the cytograms on the basis of forward and right angle light scatter characteristics. Generous gates were used so as to be assured that all lymphocytes were included. The number of monocytes was determined by labeling the cells with the monocyte-specific mAb. Positive cells were the cells that gave a fluorescence intensity greater than 99% of the background controls. Absolute lymphocyte counts were established by multiplying the white blood cell count (Coulter Electronics) by the percent of lymphocytes observed on Wright-Giemsastained blood smears. 
Results
Comparisons of PBL subsets to the duration of time post-chemotherapy
In order to relate each PBL subset to the duration of time posttherapy, we divided the population into three periods following chemotherapy; the early period, 5 to 24 months; the middle period, 25 to 49 months, and the late period, 50 to 144 months, and compared the relative and absolute number of individual PBL subsets in each to normal individuals (Tables 1 and 2 ). In our clinical study in AML (JALSG), the survival curve depressed continuously until 2 years after chemotherapy and the slope became more gentle during the next 2 years, and then the slope remained almost plateau. We supposed that the state of the immune system might be important at those points of time and divided the population at 2 years and 4 years. The range of age in normal volunteers was 22 to 65 years. It is well known that age and sex associated differences are substantial for some lymphocytes subsets (CD3, CD4 and NK cells). However, we used the unadjusted values as normal controls since the distribution of age of the patients in this study were almost similar to that of normal volunteers.
Analysis of the early period of time post-therapy comparison reveals that the percents of CD2 + and CD8 + cells were significantly lower than normal individuals.
Each PBL subset was examined in a time course fashion throughout the total duration of time post-therapy that we studied (from 5 months to 144 months). The percent and the absolute number of CD3 + DR + cells showed the persistent higher value through all periods ( Figure 1 ). There was a positive correlation between the duration of time post-therapy and the percent and the absolute number of CD4 + cells (Figure 2 ). CD4 + cells recovered from low levels to normal levels in 24 months and tended to increase beyond 49 months. Long after the chemotherapy had stopped (144 months) the CD4 + cells were normalized. The correlation between the duration of time post-therapy and CD45RA
+
CD4
+ cells was significantly positive with a normal level being achieved after 49 months (Figure 3) . The CD4 +
/CD8
+ ratio had a positive correlation with the duration of time post-therapy. The percent and the absolute cell number of CD8 + cells showed no significant relationship to the duration of time post-therapy ( Figure 4) . The percent of CD5 + B cells decreased after 24 months but some patients consistently had a higher number of CD5 + B cells than that of the normal controls ( Figure 5 ). The high percent of CD56
+ cells returned to normal after 49 months and a negative correlation was seen between the duration of time 
The appearance of auto-antibodies during CR periods
We compared the frequency of rheumatoid factor, anti-DNA and anti-nuclear antibody in each period of time post-therapy comparison. The frequency of the appearance of rheumatoid factor increased and anti-DNA antibody and anti-nuclear antibody also tended to increase beyond 24 months. The frequency of a positive test result for rheumatoid factor demonstrates a positive correlation with the value of IgG (P = 0.01) or IgM (P = 0.03), but no correlation with the number of CD5
+
Figure 2
Relationship between the percent and the number of CD4 + cells and the duration of time post-therapy. Shaded area represents normal range.
B cells or CD45RA
+ CD4 + cells (Table 3) . The NK subsets, CD16
+ and CD56 + cells were significantly depressed in the patients who were positive for rheumatoid factor and antinuclear antibodies (data not shown). Anti-DNA and antinuclear antibodies also tended to increase after 2 years.
Discussion
Recently, the application of PCR allows for the detection of minimal residual leukemic cells at 10 −4 to 10 −6 cell level. The clinical value of PCR monitoring in AML patients with the t(8;21) using the AML1-ETO fusion gene is less certain. Indeed, PCR results are often positive in CML patients after BMT, but they do not consistently indicate a poor prognosis. 3 However, several investigators have reported that the MRD was present during the early phase after chemotherapy or BMT in almost all patients with leukemia, and that MRD disappeared when patients had been maintained in CR for a long period of time. 4, 5 It has been suggested that the immune surveillance system might eradicate MRD. There have been numerous reports about the reconstitution of the immune system after BMT, 6 however, chemotherapy does differ quantitatively and qualitatively from BMT. In conjunction with BMT mega-dose drugs are administered a few days before BMT as well as the total body irradiation and allogeneic BMT can induce rejection or acute and chronic GVHD. On the other hand, depending upon the protocol used, it can take 6 months to 2 years to treat AML patients by chemotherapy. In the JALSG protocol, it takes approximately 2 years to complete the chemotherapy from the remission induction through the consolidation and maintenance therapy. 1 In the protocol for AML in JALSG, the duration of therapy is very long and cyclophosphamide and prednisolone are used in the maintenance therapy. These drugs may influence the lymphocytes subsets especially at the early period after chemotherapy.
In the present study, some subsets of PBL recovered to normal proportions by 2-4 years post-chemotherapy, but the cells of each subset in the patients displays a different phenotype from those of normal individuals and this abnormality persists for a long period. The double positive T cell subpopulation, CD45RA
+ ('naive' type T cell) recovered to normal levels by 4 years. Mackall et al 8, 9 reported the lymphocyte regeneration after intensive chemotherapy. They showed that the CD4 + T cell recovery correlated quantitatively with the appearance of CD45RA + CD4
+ T lymphocytes. Thymusdependent regeneration of CD45RA +
CD4
+ T cells occurs primarily in children, whereas as even young adults have deficiencies in this pathway. In this study, CD4
+ T cell regeneration delayed in adult patients receiving chemotherapy partially because of no residual thymic functions. A high proportion of CD3 + DR + cells (activated T cells) persisted for a longer time, but it is unclear whether this result indicates these subsets might play an active role as the immune surveillance system. With regard to the recovery of immune functions after cessation of conventional chemotherapy for acute leukemia, Alanko et al 7 showed that in most patients the reconstitution of B cells and immunoglobulin was accomplished within 6 months after discontinuation of therapy, indicating sufficient function of the immune system. Bone marrow culture studies have indicated that hematopoiesis after chemotherapy can remain abnormal for up to 10 years. One likely cause may be occult marrow damage perhaps due to previous cytotoxic chemotherapy to hematopoietic cells, regulatory environmental cells, or both.
10,11
Figure 6
Relationship between the percent and the number of CD56 + cells and the duration of time post-therapy. Shaded area represents normal range.
Figure 7
Relationship between the numbers of CD45RA A positive test result for rheumatoid factor, anti-DNA, or anti-nuclear antibody increased beyond 2 years after chemotherapy. As to the reason for the appearance of autoantibodies after chemotherapy, it is conceivable that leukemic cells are denatured or otherwise destructed by the chemotherapy and that autoreactive lymphocytes are induced by those fragments to produce autoantibodies that recognize them as modified self. Some investigators have reported that a selective loss of 
CD45RA
+ CD4 + cells plays a role in the pathogenesis of autoimmune disease. We found no significant correlation between CD45RA + CD4 + cells and autoantibodies in this study. The ␥/␦ T cell subset is also known as an autoreactive T cell subset, 12 but this subset did not increase in the present study (data not shown). CD5 + B cells are well known to be responsible for the production of autoantibodies in patients with rheumatoid arthritis, Sjö gren syndrome, and scleroderma. 13 Yet, the proportion of B cells within PBL stayed within the normal range, but the percentage of CD5 + B cells were and remained high for more than 4 years after chemotherapy. However, for patients with AML who were in CR there was a negative correlation between the number of CD5
+ B cells and a positive test result for anti-nuclear or anti-DNA antibody. There was no relationship between the number of CD5
+ B cells and a positive test result of rheumatoid factor. Therefore, it is a reasonable hypothesis that a high proportion of CD5 + B cells may indicate a very early developmental stage of B cell reconstitution and the appearance of autoantibody may be independent of CD5 + B cells. The numbers of CD16 + , CD56
+ and CD57 + cells were high at first then they gradually decreased beyond 2 years after chemotherapy. NK subsets are known to be maintained at a low level in patients with leukemia and other malignant neoplasms before therapy. It is speculative that a large number of NK cells acting as members of the immune surveillance system may hasten the removal of MRD during the early period following chemotherapy. On the contrary, impaired NK activity in early remission (2-4 months) and a gradual recovery at a later stage of remission (Ͼ6 months) were observed. + CD56 + cells. These correlations show only the proportion of each subset that takes part in the process of the reconstitution of bone marrow in each time period, but it can be speculated that each subpopulation was regulated by the other subpopulations in the immune network.
Armitage et al 15 reported on T and B cell functions after autologous BMT. Helper T cells and their functions were grossly defective. This defect closely resembled the defect observed after allo-BMT involving chemoradiotherapy. In general, helper T cell activity was more variable if the patient received only chemotherapy, but in individual patients, the defect did equal that which was observed after auto-BMT. In contrast, suppressor activity and the number of suppressor T cells equally increased in all patients. B cell functions were uniformly impaired in all patients. They concluded that chemotherapy, rather than any specific effect of BMT, was the major factor in the causation of the immune defect observed after auto-BMT. The persistent nature of the defects suggest that they are not simply a function of cellular immaturity following marrow regeneration after chemotherapy. Reports about the proportions and functions of NK cells and LAK cells are controversial. 16, 17 Most studies conclude that NK activity, lectin-dependent cellular cytotoxicity, and antibodydependent cellular cytotoxicity recover rapidly to normal levels in the majority of marrow recipients by 30 to 50 days postengraftment. yet, up to 20% of the marrow recipients can continue to have deficient cytotoxic functions for a year or more post-engraftment. Reittie et al 16 showed that NK activity for K562 cells and LAK activity are generated 4 to 6 weeks after either allogeneic or autologous BMT but do not appear after chemotherapy.
This study did not evaluate individual patients serially over time, however these data suggest that the chemotherapy administered leads to broad lymphocyte depletion with recovery of B cells and NK cells early and later recovery of CD4 + cells. Age has been shown to have important effects on immune reconstitution especially under 18 years of age, 9 and age-related effects may be an independent variable when comparing data across patients. In this study, however, the age of patients was more than 21 years and the pattern of lymphocytes recovery can be inferred.
In conclusion, our results indicate that the reconstitution of the immune system after chemotherapy needs a long period of time for total recovery to occur. There were high numbers of DR + T cells and NK cells existed for a long time. This suggests that activated T cells and NK cells might play a role in the removal of residual disease in the immune surveillance system after chemotherapy.
